Allergan Reports Third Quarter 2012 Operating Results

Allergan, Inc. (NYSE: AGN) today announced operating results for the quarter ended September 30, 2012. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on December 12, 2012 to stockholders of record on November 21, 2012.

Operating Results Attributable to Stockholders

For the quarter ended September 30, 2012:
  • Allergan reported $0.82 diluted earnings per share attributable to stockholders compared to $0.81 diluted earnings per share attributable to stockholders for the third quarter of 2011.
  • Allergan reported $1.06 non-GAAP diluted earnings per share attributable to stockholders compared to $0.92 non-GAAP diluted earnings per share attributable to stockholders for the third quarter of 2011, a 15.2 percent increase.

Product Sales

For the quarter ended September 30, 2012:
  • Allergan reported $1,391.1 million total product net sales. Total product net sales increased 6.1 percent compared to total product net sales in the third quarter of 2011. On a constant currency basis, total product net sales increased 9.4 percent compared to total product net sales in the third quarter of 2011.
    • Total specialty pharmaceuticals net sales increased 8.1 percent, or 11.4 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the third quarter of 2011.
    • Total medical devices net sales decreased 4.0 percent, or 0.3 percent on a constant currency basis, compared to total medical devices net sales in the third quarter of 2011.

“In the third quarter, Allergan again delivered solid earnings growth in spite of the strong U.S. Dollar relative to virtually all major currencies,” said David E.I. Pyott, Allergan’s Chairman of the Board, President and Chief Executive Officer. “In addition, we were pleased to mark the opening of our new R&D facility in New Jersey, as well as to announce the expansion of our relationship with Molecular Partners.”

If you liked this article you might like

Elizabeth Warren Slams Wells Fargo, Equifax: Cramer's Top Takeaways

Centene: Cramer's Top Takeaways

The Pitney Bowes Transformation: Cramer's Top Takeaways

Healthcare Trust of America, Marathon Petroleum: 'Mad Money' Lightning Round

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)